


# 글로벌 제약사 파이프라인 분석

## - MSD -

2022. 08.


국가신약개발사업단

## • 질환별 파이프라인



질환분야	개수	비중
Oncology	154	79%
Infectious	16	8%
Cardiovascular	7	4%
Metabolic	5	2.5%
Immunology	4	2%
Neuroscience	4	2%
Others	2	1%
Respiratory	1	0.5%
Musculoskeletal	1	0.5%
Hematology	1	0.5%
<b>합계</b>	<b>195개</b>	<b>100%</b>

• 물질별 파이프라인



물질	개수	비중
Small molecules	76	39%
Antibody	54	28%
Vaccine	19	10%
Protein	18	9%
ADC	12	6%
Virus	9	4.5%
Cell therapy	3	1.5%
N/A(Not Applicable)	3	1.5%
Peptide	1	0.5%
<b>합계</b>	<b>195개</b>	<b>100%</b>

## • 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Cardiovascular	Phase 3	MK-7962		sotatercept	Pulmonary arterial hypertension	Protein	Activin receptor type 2A(ACVR2A)	ACVR2A antagonist	Mono	-
2	Cardiovascular	Phase 2	MK-0616			Hypercholesterolemia	Peptide	Proprotein convertase subtilisin/kexin type 9( PCSK9)	PCSK9 inhibitor	Mono	Hanmi Pharmaceutical
3	Cardiovascular	Phase 2	MK-2060			Cardiovascular disease	Antibody	Coagulation Factor XI	Coagulation Factor XI inhibitor	Mono	-
4	Cardiovascular	Phase 2	MK-5475			Pulmonary arterial hypertension	N/A	Soluble guanylate cyclase(sGC)	sGC activator	Mono	-
5	Cardiovascular	Phase 1	MK-0657		rislenemdaz	Neurogenic orthostatic hypotension associated with Parkinson's disease	Small molecules	Glutamate Receptor Ionotropic NMDA 2B (GRIN2B)	GRIN2B antagonist	Mono	Avalo Therapeutics
6	Cardiovascular	Phase 1	MK-1242	Verquvo	vericiguat	Coronary artery disease	Small molecules	Soluble guanylate cyclase(sGC)	sGC inhibitor	Mono	Bayer
7	Cardiovascular	Phase 1	MK-8892			Pulmonary arterial hypertension	Small molecules	Soluble guanylate cyclase(sGC)	sGC inhibitor	Mono	-
8	Hematology	Phase 1	MK-1966			Hematological malignancies	Protein	IL-10	IL-10 inhibitor	Mono	-
9	Immunology	Phase 1	MK-7110			Multiple sclerosis	Protein	FCGR; DAMPs; SIGLEC10	FCGR; DAMPs; SIGLEC10 inhibitor	Mono	
10	Immunology	Phase 1	MK-7110			Rheumatoid arthritis	Protein	FCGR; DAMPs; SIGLEC10	FCGR; DAMPs; SIGLEC10 inhibitor	Mono	
11	Immunology	Phase 1	PT101			Systemic Lupus Erythematosus	Protein	IL-2R	IL-2R agonist	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
12	Immunology	Phase 1	PT101			Ulcerative Colitis	Protein	IL-2R	IL-2R agonist	Mono	-
13	Infectious	Registration	MK-4482	Lagevrio	molnupiravir	Anti-Viral COVID-19	Small molecules	RNA Directed RNA Polymerase	RNA Directed RNA Polymerase inhibitor	Mono	-
14	Infectious	Registration	V114	Vaxneuvance	pneumococcal polysaccharide [15-valent] vaccine	Streptococcal Pneumonia	Vaccine	N/A	N/A	Mono	-
15	Infectious	Phase 3	MK-1654		clesrovimab	Respiratory syncytial virus	Antibody	RSV F protein	RSV F protein inhibitor	Mono	-
16	Infectious	Phase 3	MK-4482	Lagevrio	molnupiravir	Anti-Viral COVID-19	Small molecules	RNA Directed RNA Polymerase	RNA Directed RNA Polymerase inhibitor	Mono	-
17	Infectious	Phase 3	MK-8591		islatravir	HIV-1 infection	Small molecules	Reverse transcriptase	Reverse transcriptase Inhibitor	Mono	-
18	Infectious	Phase 3	MK-8591A		doravirine +islatravir	HIV-1 infection	Small molecules	Reverse transcriptase	Reverse transcriptase Inhibitor	Combination	-
19	Infectious	Phase 2	MK-8591B		islatravir+MK-8507	HIV 1 infection	Small molecules	Reverse transcriptase	Reverse transcriptase inhibitor	Combination	-
20	Infectious	Phase 2	V116			Pneumococcal vaccine	Vaccine	N/A	N/A	Mono	-
21	Infectious	Phase 2	V160			Cytomegalovirus vaccine	Vaccine	N/A	N/A	Mono	-
22	Infectious	Phase 2	V184			Chikungunya virus	Vaccine	N/A	N/A	Mono	-
23	Infectious	Phase 1	Lassa Fever Vaccine			Vaccinate against Lassa hemorrhagic fever virus infection	Vaccine	N/A	N/A	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
24	Infectious	Phase 1	MBX-701			Chronic HCV genotype 1 infection	Small molecules	NS5B	NS5B inhibitor	Mono	Microbiotix
25	Infectious	Phase 1	MRK-1777			Respiratory syncytial virus	Vaccine	N/A	N/A	Mono	Moderna
26	Infectious	Phase 1	MV-ZIKA-101			Zika virus	Vaccine	N/A	N/A	Mono	-
27	Infectious	Phase 1	TMV-083			COVID-19	Vaccine	SARS-CoV-2 S	SARS-CoV-2 S inhibitor	Mono	Coalition for Epidemic Preparedness Innovations
28	Infectious	Phase 1	V181			Dengue virus infection	Vaccine	N/A	N/A	Mono	-
29	Metabolic	Phase 2	MK-3655			Non-alcoholic Steatohepatitis (NASH)	Antibody	Fibroblast growth factor or receptor 1(FGFR1)	FGFR1 agonist	Mono	-
30	Metabolic	Phase 2	MK-6024		efinopegdutide	Non-alcoholic Steatohepatitis (NASH)	Protein	Glucagon receptor (GCGR)	GCGR agonist	Mono	-
31	Metabolic	Phase 1	ACE-1334			Systemic sclerosis-related interstitial lung disease	Protein	TGFB1, TGFB3	TGFB1; TGFB3 inhibitor	Mono	-
32	Metabolic	Phase 1	MK-3655			Type II diabetes	Antibody	Fibroblast growth factor or receptor(FGFR)	FGFR agonist	Mono	NGM Biopharmaceuticals
33	Metabolic	Phase 1	MK-3655			Metabolic diseases	Antibody	Fibroblast growth factor or receptor(FGFR)	FGFR agonist	Mono	NGM Biopharmaceuticals
34	Musculoskeletal	Phase 2	MK-7075		miransertib mesylate	Overgrowth syndrome	Small molecules	AKT3	AKT3 inhibitor	Mono	-
35	Neuroscience	Phase 2	MK-1942			Resistant depression	N/A	N/A	N/A	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
36	Neuroscience	Phase 2	MK-8189			Schizophrenia	N/A	Phosphodiesterase 10A1(PDE10A)	Phosphodiesterase 10A1(PDE10A) inhibitor	Mono	-
37	Neuroscience	Phase 1	BNC375			Alzheimer's disease	Small molecules	Nicotinic acetylcholine receptor alpha 7 (CHRNA7)	CHRNA7 agonist	Mono	Bionomics
38	Neuroscience	Phase 1	MK-8719			Progressive supranuclear palsy	Small molecules	O-GlcNAcase	O-GlcNAcase inhibitor	Mono	Alectos Therapeutics
39	Oncology	Phase 3	MK-1308A		quavonlimab+ pembrolizumab	Renal cell carcinoma	Antibody	CTLA-4; PD-1	CTLA-4 antagonist; PD-1 antagonist	Combination	Akeso
40	Oncology	Phase 3	MK-3475	Keytruda	pembrolizumab	Small cell Lung cancer	Antibody	PD-1	PD-1 antagonist	Mono	-
41	Oncology	Phase 3	MK-3475	Keytruda	pembrolizumab	Prostate cancer	Antibody	PD-1	PD-1 antagonist	Mono	-
42	Oncology	Phase 3	MK-3475	Keytruda	pembrolizumab	Ovarian cancer	Antibody	PD-1	PD-1 antagonist	Mono	-
43	Oncology	Phase 3	MK-3475	Keytruda	pembrolizumab	Mesothelioma cancer	Antibody	PD-1	PD-1 antagonist	Mono	-
44	Oncology	Phase 3	MK-3475	Keytruda	pembrolizumab	Biliary tract cancer	Antibody	PD-1	PD-1 antagonist	Mono	-
45	Oncology	Phase 3	MK-3475	Keytruda	pembrolizumab	Hepatocellular carcinoma	Antibody	PD-1	PD-1 antagonist	Mono	-
46	Oncology	Phase 3	MK-3475	Keytruda	pembrolizumab	Gastric cancer	Antibody	PD-1	PD-1 antagonist	Mono	-
47	Oncology	Phase 3	MK-3475	Keytruda	pembrolizumab	Cutaneous squamous cell carcinoma	Antibody	PD-1	PD-1 antagonist	Mono	-
48	Oncology	Phase 3	MK-3475		pembrolizumab subcutaneous	NSCLC	Antibody	PD-1	PD-1 antagonist	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
49	Oncology	Phase 3	MK-4280A		favezelimab+ pembrolizumab	Colorectal cancer	Antibody	LAG3; PD-1	LAG3 antagonist; PD-1 antagonist	Combination	-
50	Oncology	Phase 3	MK-6482	Welireg	belzutifan	Renal cell carcinoma	Small molecules	EPAS1	EPAS1 inhibitor	Mono	-
51	Oncology	Phase 3	MK-7119	Tukysa	tucatinib	Breast cancer	Small molecules	EGFR2	EGFR2 inhibitor	Mono	-
52	Oncology	Phase 3	MK-7339	Lynparza	olaparib	Small cell Lung cancer	Small molecules	PARP	PARP inhibitor	Mono	-
53	Oncology	Phase 3	MK-7339	Lynparza	olaparib	NSCLC	Small molecules	PARP	PARP inhibitor	Mono	-
54	Oncology	Phase 3	MK-7339	Lynparza	olaparib	Colorectal cancer	Small molecules	PARP	PARP inhibitor	Mono	-
55	Oncology	Phase 3	MK-7684A		vibostolimab+ pembrolizumab	Small cell Lung cancer	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Combination	-
56	Oncology	Phase 3	MK-7684A		vibostolimab+ pembrolizumab	NSCLC	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Combination	-
57	Oncology	Phase 3	MK-7902	Lenvima	lenvatinib mesylate	Head&neck squamous cell carcinoma	Small molecules	VEGF	VEGF inhibitor	Mono	-
58	Oncology	Phase 3	MK-7902	Lenvima	lenvatinib mesylate	NSCLC	Small molecules	VEGF	VEGF inhibitor	Mono	-
59	Oncology	Phase 3	MK-7902	Lenvima	lenvatinib mesylate	Melanoma cancer	Small molecules	VEGF	VEGF inhibitor	Mono	-
60	Oncology	Phase 3	MK-7902	Lenvima	lenvatinib mesylate	Gastric	Small molecules	VEGF	VEGF inhibitor	Mono	-
61	Oncology	Phase 3	MK-7902	Lenvima	lenvatinib mesylate	Esophageal cancer	Small molecules	VEGF	VEGF inhibitor	Mono	-



No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
62	Oncology	Phase 3	MK-7902	Lenvima	lenvatinib mesylate	Colorectal cancer	Small molecules	VEGF	VEGF inhibitor	Mono	-
63	Oncology	Phase 2	MK-0482			NSCLC	Antibody	Leukocyte immunoglobulin like receptor subfamily B member4(LILRB4)	LILRB4 antagonist	Mono	-
64	Oncology	Phase 2	MK-1026		nemtabrutinib	Hematological malignancies	Small molecules	BTK	BTK inhibitor	Mono	-
65	Oncology	Phase 2	MK-1308		quavonlimab	NSCLC	Antibody	CTLA-4	CTLA-4 antagonist	Mono	-
66	Oncology	Phase 2	MK-1308A		quavonlimab+pembrolizumab	Advance solid tumors	Antibody	CTLA-4; PD-1	CTLA-4 antagonist; PD-1 antagonist	Combination	-
67	Oncology	Phase 2	MK-1308A		quavonlimab+pembrolizumab	Colorectal cancer	Antibody	CTLA-4; PD-1	CTLA-4 antagonist; PD-1 antagonist	Combination	-
68	Oncology	Phase 2	MK-1308A		quavonlimab+pembrolizumab	Hepatocellular carcinoma	Antibody	CTLA-4; PD-1	CTLA-4 antagonist; PD-1 antagonist	Combination	-
69	Oncology	Phase 2	MK-1308A		quavonlimab+pembrolizumab	Melanoma cancer	Antibody	CTLA-4; PD-1	CTLA-4 antagonist; PD-1 antagonist	Combination	-
70	Oncology	Phase 2	MK-1308A		quavonlimab+pembrolizumab	Small cell Lung cancer	Antibody	CTLA-4; PD-1	CTLA-4 antagonist; PD-1 antagonist	Combination	-
71	Oncology	Phase 2	MK-2140		zilovetamab vedotin	Breast cancer	ADC	Receptor tyrosine kinase-like orphan receptor 1 (ROR1)	Cytotoxic to cells expressing ROR1	Mono	-
72	Oncology	Phase 2	MK-2140		zilovetamab vedotin	Hematological malignancies	ADC	Receptor tyrosine kinase-like orphan receptor 1 (ROR1)	Cytotoxic to cells expressing ROR1	Mono	-
73	Oncology	Phase 2	MK-2140		zilovetamab vedotin	NSCLC	ADC	Receptor tyrosine kinase-like orphan receptor 1 (ROR1)	Cytotoxic to cells expressing ROR1	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
74	Oncology	Phase 2	MK-3475	Keytruda	pembrolizumab	Advance solid tumors	Antibody	PD-1	PD-1 antagonist	Mono	-
75	Oncology	Phase 2	MK-4280		favezelimab	NSCLC	Antibody	LAG3	LAG3 antagonist	Mono	-
76	Oncology	Phase 2	MK-4280		favezelimab	Hematological malignancies	Antibody	LAG3	LAG3 antagonist	Mono	-
77	Oncology	Phase 2	MK-4280A		favezelimab+ pembrolizumab	Renal cell carcinoma	Antibody	LAG3; PD-1	LAG3 antagonist; PD-1 antagonist	Combination	-
78	Oncology	Phase 2	MK-4280A		favezelimab+ pembrolizumab	Small cell Lung cancer	Antibody	LAG3; PD-1	LAG3 antagonist; PD-1 antagonist	Combination	-
79	Oncology	Phase 2	MK-4830			NSCLC	Antibody	Leukocyte immunoglo bulin like receptor subf amily B member2 (LILRB2)	LILRB2 antagonist	Mono	-
80	Oncology	Phase 2	MK-4830			Colorectal cancer	Antibody	Leukocyte immunoglo bulin like receptor subf amily B member2 (LILRB2)	LILRB2 antagonist	Mono	-
81	Oncology	Phase 2	MK-4830			Renal cell carcinoma	Antibody	Leukocyte immunoglo bulin like receptor subf amily B member2 (LILRB2)	LILRB2 antagonist	Mono	-
82	Oncology	Phase 2	MK-4830			Small cell Lung cancer	Antibody	Leukocyte immunoglo bulin like receptor subf amily B member2 (LILRB2)	LILRB2 antagonist	Mono	-
83	Oncology	Phase 2	MK-5890		boserolimab	NSCLC	Antibody	CD27	CD27 agonist	Mono	Chinook Therapeutics

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
84	Oncology	Phase 2	MK-5890		boserolimab	Small cell Lung cancer	Antibody	CD27	CD27 agonist	Mono	-
85	Oncology	Phase 2	MK-6440		ladiratuzumab vedotin	Esophageal cancer	ADC	Solute carrier family 39 zinc transporter member 6(SLC39A6)	SLC39A6 inhibitor	Mono	-
86	Oncology	Phase 2	MK-6440		ladiratuzumab vedotin	Gastric cancer	ADC	Solute carrier family 39 zinc transporter member 6(SLC39A6)	SLC39A6 inhibitor	Mono	-
87	Oncology	Phase 2	MK-6440		ladiratuzumab vedotin	Head&neck squamous cell carcinoma	ADC	Solute carrier family 39 zinc transporter member 6(SLC39A6)	SLC39A6 inhibitor	Mono	-
88	Oncology	Phase 2	MK-6440		ladiratuzumab vedotin	Melanoma cancer	ADC	Solute carrier family 39 zinc transporter member 6(SLC39A6)	SLC39A6 inhibitor	Mono	-
89	Oncology	Phase 2	MK-6440		ladiratuzumab vedotin	Prostate cancer	ADC	Solute carrier family 39 zinc transporter member 6(SLC39A6)	SLC39A6 inhibitor	Mono	-
90	Oncology	Phase 2	MK-6440		ladiratuzumab vedotin	Small cell Lung cancer	ADC	Solute carrier family 39 zinc transporter member 6(SLC39A6)	SLC39A6 inhibitor	Mono	-
91	Oncology	Phase 2	MK-6440		ladiratuzumab vedotin	NSCLC	ADC	Solute carrier family 39 zinc transporter member 6(SLC39A6)	SLC39A6 inhibitor	Mono	-
92	Oncology	Phase 2	MK-6440		ladiratuzumab vedotin	Breast cancer	ADC	Solute carrier family 39 zinc transporter member 6(SLC39A6)	SLC39A6 inhibitor	Mono	-
93	Oncology	Phase 2	MK-6482	Welireg	belzutifan	Rare cancers	Small molecules	EPAS1	EPAS1 inhibitor	Mono	-
94	Oncology	Phase 2	MK-6482	Welireg	belzutifan	pancreatic cancer	Small molecules	EPAS1	EPAS1 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
95	Oncology	Phase 2	MK-6482	Welireg	belzutifan	Hepatocellular carcinoma	Small molecules	EPAS1	EPAS1 inhibitor	Mono	-
96	Oncology	Phase 2	MK-6482	Welireg	belzutifan	Colorectal cancer	Small molecules	EPAS1	EPAS1 inhibitor	Mono	-
97	Oncology	Phase 2	MK-6482	Welireg	belzutifan	Certain VHL tumors	Small molecules	EPAS1	EPAS1 inhibitor	Mono	-
98	Oncology	Phase 2	MK-6482	Welireg	belzutifan	Biliary tract cancer	Small molecules	EPAS1	EPAS1 inhibitor	Mono	-
99	Oncology	Phase 2	MK-7119	Tukysa	tucatinib	Colorectal cancer	Small molecules	EGFR2	EGFR2 inhibitor	Mono	-
100	Oncology	Phase 2	MK-7119	Tukysa	tucatinib	Endometrial cancer	Small molecules	EGFR2	EGFR2 inhibitor	Mono	-
101	Oncology	Phase 2	MK-7119	Tukysa	tucatinib	Advance solid tumors	Small molecules	EGFR2	EGFR2 inhibitor	Mono	-
102	Oncology	Phase 2	MK-7119	Tukysa	tucatinib	Bladder cancer	Small molecules	EGFR2	EGFR2 inhibitor	Mono	-
103	Oncology	Phase 2	MK-7119	Tukysa	tucatinib	NSCLC	Small molecules	EGFR2	EGFR2 inhibitor	Mono	-
104	Oncology	Phase 2	MK-7119	Tukysa	tucatinib	Gastric cancer	Small molecules	EGFR2	EGFR2 inhibitor	Mono	-
105	Oncology	Phase 2	MK-7119	Tukysa	tucatinib	Biliary tract cancer	Small molecules	EGFR2	EGFR2 inhibitor	Mono	-
106	Oncology	Phase 2	MK-7119	Tukysa	tucatinib	Cervical cancer	Small molecules	EGFR2	EGFR2 inhibitor	Mono	-
107	Oncology	Phase 2	MK-7339	Lynparza	olaparib	Advance solid tumors	Small molecules	PARP	PARP inhibitor	Mono	-
108	Oncology	Phase 2	MK-7684		vibostolimab	Melanoma cancer	Antibody	TIGIT	TIGIT antagonist	Mono	-
109	Oncology	Phase 2	MK-7684A		vibostolimab+ pembrolizumab	Prostate cancer	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
110	Oncology	Phase 2	MK-7684A		vibostolimab+ pembrolizumab	Hematologic malignancies	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Mono	-
111	Oncology	Phase 2	MK-7684A		vibostolimab+ pembrolizumab	Head&neck squamous cell carcinoma	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Mono	-
112	Oncology	Phase 2	MK-7684A		vibostolimab+ pembrolizumab	Hepatocellular carcinoma	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Combination	-
113	Oncology	Phase 2	MK-7684A		vibostolimab+ pembrolizumab	Esophageal cancer	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Combination	-
114	Oncology	Phase 2	MK-7684A		vibostolimab+ pembrolizumab	Endometrial cancer	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Combination	-
115	Oncology	Phase 2	MK-7684A		vibostolimab+ pembrolizumab	Cervical cancer	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Combination	-
116	Oncology	Phase 2	MK-7684A		vibostolimab+ pembrolizumab	Breast cancer	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Combination	-
117	Oncology	Phase 2	MK-7684A		vibostolimab+ pembrolizumab	Biliary tract cancer	Antibody	TIGIT; PD-1	TIGIT antagonist; PD-1 antagonist	Combination	-
118	Oncology	Phase 2	MK-7902	Lenvima	lenvatinib mesylate	Small cell Lung cancer	Small molecules	VEGF	VEGF inhibitor	Mono	-
119	Oncology	Phase 2	MK-7902	Lenvima	lenvatinib mesylate	Prostate cancer	Small molecules	VEGF	VEGF inhibitor	Mono	-
120	Oncology	Phase 2	MK-7902	Lenvima	lenvatinib mesylate	pancreatic cancer	Small molecules	VEGF	VEGF inhibitor	Mono	-
121	Oncology	Phase 2	MK-7902	Lenvima	lenvatinib mesylate	Blioblastoma	Small molecules	VEGF	VEGF inhibitor	Mono	-
122	Oncology	Phase 2	MK-7902	Lenvima	lenvatinib mesylate	Biliary tract cancer	Small molecules	VEGF	VEGF inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
123	Oncology	Phase 2	V937			Cutaneous squamous cell carcinoma	Virus	Intercellular adhesion molecule1(ICAM1)	Oncolytic virus	Mono	-
124	Oncology	Phase 2	V937			Melanoma cancer	Virus	Intercellular adhesion molecule1(ICAM1)	Oncolytic virus	Mono	-
125	Oncology	Phase 2	V937			Head&neck squamous cell carcinoma	Virus	Intercellular adhesion molecule1(ICAM1)	Oncolytic virus	Mono	-
126	Oncology	Phase 2	V937			Breast cancer	Virus	Intercellular adhesion molecule1(ICAM1)	Oncolytic virus	Mono	-
127	Oncology	Phase 2	V937			Solid tumors	Virus	Intercellular adhesion molecule1(ICAM1)	Oncolytic virus	Mono	-
128	Oncology	Phase 1	ADG106			Advanced/metastatic solid/hematological malignancies in combination with pembrolizumab	Antibody	Tumor necrosis factor (TNF)	TNF agonist	Combination	Adagene
129	Oncology	Phase 1	AMG 386		trebananib	Solid tumors	Protein	ANG1; ANG2	ANG1; ANG2 inhibitor	Combination	Amgen
130	Oncology	Phase 1	ARQ 092		miransertib	Endometrial cancer	Small molecules	Protein kinase B(PKB)	PKB inhibitor	Mono	-
131	Oncology	Phase 1	ARQ 092		miransertib	Lymphoma	Small molecules	Protein kinase B(PKB)	PKB inhibitor	Mono	-
132	Oncology	Phase 1	ARQ 092		miransertib	Ovarian cancer	Small molecules	Protein kinase B(PKB)	PKB inhibitor	Mono	-
133	Oncology	Phase 1	ARQ 092		miransertib	Advanced solid tumors, recurrent malignant lymphoma	Small molecules	Protein kinase B(PKB)	PKB inhibitor	Mono	-
134	Oncology	Phase 1	ARQ 751			Solid tumors	Small molecules	Protein kinase B(PKB)	PKB inhibitor	Mono	-
135	Oncology	Phase 1	ARQ 761			Advanced solid tumors	Small molecules	NAD(P)H dehydrogenase quinone 1(NQO1)	NQO1 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
136	Oncology	Phase 1	BAL087		derazantinib	Urothelial carcinoma	Small molecules	Fibroblast growth factor receptor(FGFR)	FGFR inhibitor	Mono	Sinovant Sciences
137	Oncology	Phase 1	BAL087		derazantinib	Advanced gastric cancer	Small molecules	Fibroblast growth factor receptor(FGFR)	FGFR inhibitor	Mono	-
138	Oncology	Phase 1	BAL087		derazantinib	Advanced solid tumors	Small molecules	Fibroblast growth factor receptor(FGFR)	FGFR inhibitor	Mono	Roivant Sciences
139	Oncology	Phase 1	BI-1206			Solid tumors in combination with pembrolizumab	Antibody	Fc gamma receptor 2b(FCGR2B)	FCGR2B antagonist	Combination	CASI Pharmaceuticals
140	Oncology	Phase 1	CT-0508			Metastatic solid tumors	Cell Therapy	HER2	HER2 inhibitor	Combination	Carisma Therapeutics
141	Oncology	Phase 1	CUE-101			Head and neck squamous cell carcinoma	Protein	IL-2R	IL-2R agonist	Mono	Cue Biopharma
142	Oncology	Phase 1	EOC103		entinostat	Microsatellite stable colorectal cancer	Small molecules	HDAC	HDAC inhibitor	Mono	Bayer
143	Oncology	Phase 1	EOC103		entinostat	Melanoma	Small molecules	HDAC	HDAC inhibitor	Mono	Bayer
144	Oncology	Phase 1	FF-10832		gemcitabine hydrochloride	Solid tumors	Small molecules	Ribonucleoside reductase(RRM)	RRM inhibitor	Mono	Fujifilm
145	Oncology	Phase 1	G-100			Metastatic soft tissue sarcoma	Vaccine	TLR4	TLR4 agonist	Mono	-
146	Oncology	Phase 1	G-100			Merkel cell carcinoma	Vaccine	TLR4	TLR4 agonist	Mono	-
147	Oncology	Phase 1	G-100			Follicular non-Hodgkin lymphoma	Vaccine	TLR4	TLR4 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
148	Oncology	Phase 1	GI-101			Advanced/metastatic solid tumors ; Treat advanced or metastatic solid tumors in combination with Imfinzi ; Treat solid tumors in combination with keytruda; Treat advanced or metastatic solid tumors in combination with lenvatinib; Treat advanced or metastatic solid tumors in combination with pembrolizumab; Treat advanced or metastatic solid tumors in combination with local radiotherapy	Protein	ILRL2, CTLA-4	ILRL2, CTLA-4 inhibitor	Combination	GI Innovation
149	Oncology	Phase 1	ID-LV305, LV305			Solid tumors	Virus	Cancer/testis antigen 1B(CTAG1B)	N/A	Mono	-
150	Oncology	Phase 1	IN10018			Pancreatic cancer	Small molecules	FAK	FAK inhibitor	Combination	Boehringer Ingelheim
151	Oncology	Phase 1	IO102-IO103			1L urothelial bladder cancer	Vaccine	Indoleamine 2,3-dioxygenase (IDO);PD-L1	IDO; PD-L1 inhibitor	Combination	IO Biotech
152	Oncology	Phase 1	IO102-IO103			1L head and neck squamous cell carcinoma	Vaccine	Indoleamine 2,3-dioxygenase (IDO);PD-L1	IDO; PD-L1 inhibitor	Combination	IO Biotech
153	Oncology	Phase 1	IO102-IO103			1L NSCLC	Vaccine	Indoleamine 2,3-dioxygenase (IDO);PD-L1	IDO; PD-L1 inhibitor	Combination	IO Biotech
154	Oncology	Phase 1	IO-108			Advanced/refractory solid tumors	Antibody	LILRB2	LILRB2 antagonist	Combination	Immune-Onc
155	Oncology	Phase 1	IO-202			Advanced solid tumors	Antibody	LILRB4	LILRB4 inhibitor	Combination	Immune-Onc
156	Oncology	Phase 1	LVGN6051			Cancer	Antibody	4-1BBL	4-1BBL inhibitor	Mono	Lyvgen Biopharma



No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
157	Oncology	Phase 1	MK-1026		nemtabrutinib	Chronic lymphocytic leukemia	Small molecules	BTK	BTK inhibitor	Mono	-
158	Oncology	Phase 1	MK-1027		nemtabrutinib	Small lymphocytic lymphoma	Small molecules	BTK	BTK inhibitor	Mono	-
159	Oncology	Phase 1	MK-1028		nemtabrutinib	Mantle cell lymphoma	Small molecules	BTK	BTK inhibitor	Mono	-
160	Oncology	Phase 1	MK-1029		nemtabrutinib	Waldenstrom's macroglobulinemia	Small molecules	BTK	BTK inhibitor	Mono	-
161	Oncology	Phase 1	MK-1454			Advanced/metastatic lymphoma	Small molecules	Transmembrane protein 173(TMEM173)	TMEM173 inhibitor	Mono	-
162	Oncology	Phase 1	MK-1454			Advanced/metastatic solid tumors	Small molecules	Transmembrane protein 173(TMEM173)	TMEM173 inhibitor	Mono	-
163	Oncology	Phase 1	MK-2140		zilovertamab vedotin	Relapsed/refractory hematologic cancers	ADC	Receptor tyrosine kinase-like orphan receptor 1 (ROR1)	Cytotoxic to cells expressing ROR1	Mono	-
164	Oncology	Phase 1	MK-2206			Recurrent melanoma	Small molecules	Protein kinase B(PKB)	PKB inhibitor	Mono	-
165	Oncology	Phase 1	MK-2206			Recurrent renal cancer	Small molecules	Protein kinase B(PKB)	PKB inhibitor	Mono	-
166	Oncology	Phase 1	MK-2206			Solid tumors	Small molecules	Protein kinase B(PKB)	PKB inhibitor	Mono	-
167	Oncology	Phase 1	MK-3475	Keytruda	pembrolizumab	Recurrent glioblastoma multiforme	Antibody	PD-1	PD-1 inhibitor	Mono	Taiho Pharmaceutical
168	Oncology	Phase 1	MK-4166			Solid tumors	Antibody	Tumor necrosis factor receptor(TNFR)	TNFR inhibitor	Mono	
169	Oncology	Phase 1	MK-4827	Zejula	niraparib	Advanced cancer	Small molecules	PARP-2, PARP-1	PARP-2, PARP-1 inhibitor	Mono	GSK, Takeda, Zai Lab

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
170	Oncology	Phase 1	MK-7339	Lynparza	olaparib	Relapsed glioblastoma multiforme	Small molecules	PARP	PARP inhibitor	Mono	AstraZeneca
171	Oncology	Phase 1	MK-8033			c-MET-positive solid tumors	Small molecules	c-MET	c-MET inhibitor	Mono	Ascentage Pharma
172	Oncology	Phase 1	MK-8628			Hematologic malignancies	Small molecules	BRD2, BRD3, BRD4	BRD2, BRD3, BRD4 inhibitor	Mono	Mitsubishi Tanabe Pharma
173	Oncology	Phase 1	MK-8628			Advanced solid tumors	Small molecules	BRD2, BRD3, BRD4	BRD2, BRD3, BRD4 inhibitor	Mono	Mitsubishi Tanabe Pharma
174	Oncology	Phase 1	MRNA-5671			Colorectal cancer	Vaccine	KRAS	KRAS inhibitor	Mono	Moderna
175	Oncology	Phase 1	MRNA-5671			NSCLC	Vaccine	KRAS	KRAS inhibitor	Mono	Moderna
176	Oncology	Phase 1	MRNA-5671			Treat pancreatic cancer	Vaccine	KRAS	KRAS inhibitor	Mono	Moderna
177	Oncology	Phase 1	NL-201			Advanced/refractory/metastatic solid tumors	Protein	IL-2, IL-15	IL-2, IL-15 inhibitor	Combination	Neoleukin Therapeutics
178	Oncology	Phase 1	ONCR-177			Advanced/refractory/metastatic solid tumors	Virus	FLT3LG, MIP1B, IL-12, PD-1, CTLA4	Oncolytic virus	Combination	Oncorus
179	Oncology	Phase 1	PEG-IL-10		pegilodecakin	TNBC	Protein	IL-10 receptor	IL-10 receptor inhibitor	Mono	Eli Lilly
180	Oncology	Phase 1	PEG-IL-10		pegilodecakin	Colorectal cancer	Protein	IL-11 receptor	IL-11 receptor inhibitor	Mono	Eli Lilly
181	Oncology	Phase 1	PEG-IL-10		pegilodecakin	Hematologic malignancies	Protein	IL-12 receptor	IL-12 receptor inhibitor	Mono	Eli Lilly
182	Oncology	Phase 1	PEG-IL-10		pegilodecakin	Melanoma	Protein	IL-13 receptor	IL-13 receptor inhibitor	Mono	Eli Lilly

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
183	Oncology	Phase 1	PEG-IL-10		pegilodecakin	Metastatic renal cell cancer	Protein	IL-14 receptor	IL-14 receptor inhibitor	Mono	Eli Lilly
184	Oncology	Phase 1	PEG-IL-10		pegilodecakin	Advanced solid tumors	Protein	IL-15 receptor	IL-15 receptor inhibitor	Mono	Eli Lilly
185	Oncology	Phase 1	PRIME IL-15			Hematologic tumors	Cell Therapy	CD4	CD4 inhibitor	Mono	Repertoire Immune Medicines
186	Oncology	Phase 1	PRIME IL-15			Solid tumors	Cell Therapy	CD4	CD4 inhibitor	Mono	Repertoire Immune Medicines
187	Oncology	Phase 1	SRF617			Advanced solid tumors	Antibody	ENTPD1	ENTPD1 inhibitor	Mono	Surface Oncology
188	Oncology	Phase 1	TILT-123			Platinum resistant or refractory ovarian cancer	Virus	Tumor necrosis factor (TNF)	Oncolytic virus	Combination	TILT Biothe rapeutics
189	Oncology	Phase 1	V-937	Cavatak	gebasaxturev	NSCLC	Virus	Intercellular adhesion molecule-1(ICAM-1)	Oncolytic virus	Mono	-
190	Oncology	Phase 1	V-937	Cavatak	gebasaxturev	Solid tumors	Virus	Intercellular adhesion molecule-1(ICAM-1)	Oncolytic virus	Mono	-
191	Oncology	Phase 1			paclitaxel+en cequidar	NSCLC	Small molecules	ATP-binding cassette sub-family B member 1 (ABCB1)	ABCB1 inhibitor	Combination	Hanmi Phar maceutical
192	Oncology	Phase 1		Zolinsa	vorinostat	High risk uveal melanoma	Small molecules	HDAC	HDAC inhibitor	Mono	Taiho Phar maceutical
193	Others	Phase 1	MK-0677	Oratrope	ibutamoren	Children born small for gestatio nal age	Small molecules	Growth hormone rece ptor(GHSR)	GHSR inhibitor	Mono	Lumos Pharma

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
194	Others	Phase 1	MK-0677	Oratrope	ibutamoren	Turner syndrome	Small molecules	Growth hormone receptor(GHSR)	GHSR inhibitor	Mono	Lumos Pharma
195	Respiratory	Registration	MK-7264		gefapixant	Cough	Small molecules	P2X3	P2X3 antagonist	Mono	Roche

자료: MSD 홈페이지, BioCentury, GlobalData